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Abstract
Purpose: [18F]VM4-037 was recently developed as a positron emission tomography (PET) tracer
for the detection of carbonic anhydrase IX (CAIX), a tumor-specific protein upregulated under
hypoxic conditions. In this study, the accumulation of [18F]VM4-037 was determined in two
CAIX-expressing preclinical human tumor models.
Procedures: U373 and HT29 tumor-bearing animals were injected with [18F]VM4-037 and
underwent microPET imaging up to 4 h post-injection (p.i.). Biodistribution throughout the
different organs was assessed at 2 and 4 h p.i. using gamma counting.
Results: MicroPET imaging showed high [18F]VM4-037 uptake in the abdominal region, and
biodistribution revealed high radioactivity in the kidney, ileum, colon, liver, stomach, and bladder.
Although high CAIX expression was confirmed in both tumor models, tumor uptake assessed
with microPET and biodistribution experiments was comparable to background tissues.
Conclusions: In this study, [18F]VM4-037 does not specifically accumulate in CAIX-expressing
tumors, indicating that the tracer is not suitable for the detection of CAIX.
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Introduction
Carbonic anhydrase IX (CAIX) is a tumor-specificprotein upregulated in response to hypoxia [1]. Low
oxygen concentrations are a common phenomenon in solid
tumors [2]. One of the key adaptations to this condition is
the stabilization of Bhypoxia-inducible factor^ (HIF) [3],
which regulates the transcription of several genes including
the CA9 gene [1]. CAIX plays a main role in the regulation
of the cellular pH. By catalyzing the reaction of CO2 and
H2O to bicarbonate and a proton, CAIX preserves the stable
intracellular environment and acidifies the extracellular
environment [4]. Furthermore, the expression of CAIX has
been found to be a negative predictor for disease-free
survival [5]. Inhibition of CAIX function by targeted drugs
would therefore be a promising anticancer approach.
Several specific CAIX inhibitors have been developed
and described [6]. Recent publications show that inhibition
of CAIX results in reduced tumor growth in vivo, especially
in combination with radiotherapy [7, 8]. Furthermore,
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in vitro and in vivo results indicate the potential involvement
of CAIX in processes like metastasis and invasion [9–11].
Before clinical implementation of these specific inhibitors, it
would be extremely valuable to have a screening method to
assess the CAIX status of tumors. This would allow patient
selection before the start of treatment. A new promising
imaging radiopharmaceutical, [18F]VM4-037, has recently
been proposed. So far, this radiopharmaceutical has been
tested in healthy human volunteers, demonstrating the safety
of [18F]VM4-037 [12]. We assessed the tumor-specific
uptake of this positron emission tomography (PET) radio-
pharmaceutical in two preclinical CAIX-expressing tumor
models using microPET and biodistribution.
Material and Methods
Synthesis of [18F]VM4-037
Synthesis of radioactive-labeled (S)-3-(4-(2-[18F]fluoroethoxy)phenyl)-
2-(3-methyl-2-(4-((2-sulfamoylbenzo[d]thiazol-6-yloxy)methyl)-1H-
1,2,3-triazol-1-yl)butanamido) propanoic acid, also referred to as
[18F]VM4-037, was performed as described previously [12]. The
high-performance liquid chromatography (HPLC)-isolated [18F]VM4-
037 fractions demonstrated a radiochemical purity always 999 %.
Specific activity was typically in the range of 15–50 GBq/μmol and the
decay-corrected synthesis yield was 7–9 %.
Animal and Tumor Model, PET Acquisition,
and Metabolism
All animal experiments were approved by the ethical committee of
the local universities. All applicable institutional and national
guidelines for the care and use of animals were followed. U373
glioma (ATCC HTB-17) or HT29 (ATCC HTB-38) colorectal
adenocarcinoma cells, resuspended in Basement Membrane Matrix
(MatrigelTM BD Biosciences), were subcutaneously injected into
the lateral flank or the shoulder of NMRI (nu/nu) mice. Tumor
volume was measured on a regular basis using a Vernier caliper and
calculated by the formula A×B×C×π/6 in which A, B, and C are the
three orthogonal diameters of the tumor, each corrected for the
thickness of the skin. The minimum tumor volume for inclusion
was 9300 mm3 to ensure clear visualization on the microPET.
Upon an average tumor volume of 597 mm3 (range 358–981) and
1192 mm3 (range 463–1745) for U373 (n=4) and HT29 (n=3),
respectively, PET acquisition was performed under isoflurane
anesthesia (induction 4 %, maintenance 1–2 %).
PET imaging was performed using the Focus 120 microPET
(Siemens Medical Solutions USA, Inc.) with an axial field of view
(FOV) of 7.6 cm, a transaxial FOV of 10 cm, and a resolution of
approximately 1.5 mm. The animals were positioned in the center
of the FOV of the microPET using a laser-positioning system.
A bolus injection of [18F]VM4-037 (3.79±0.55 MBq) was
given via a catheter placed in the lateral tail vein. PET
acquisitions for the U373 tumor model (n=4 mice, all bearing
a tumor) were performed at time points 0, 120, and 240 min
post-injection (p.i.) using a 15-min emission scan. Image
acquirement of the HT29 tumor model (n=4 mice, three of
which had a tumor) was performed at 30, 60, 90, and 120 min
after injection using a 10-min emission scan. Each scan was
corrected for random counts, dead time, and decay. List mode
acquisition and reconstruction were performed as previously
described [13]. Images were visualized and analyzed using
ASIPro VM software (version 6.3.3.0).
Biodistribution
After the final PET acquisition, animals were sacrificed and
prepared for biodistribution. The tumor, blood, skin, bladder, heart,
lungs, liver, spleen, stomach, ileum, colon, kidney, lymph nodes,
salivary gland, muscle, and brain were weighed, and the amount of
radioactivity in each organ was assessed using a gamma-well
counter (1480 Wallac Wizard 3″ automatic γ-counter; PerkinElmer,
Inc.). Tumors were halved, after which one piece was used for
gamma counting and the other half was snap frozen for protein
isolation. Disintegrations were counted for 1 min for each sample
using an energy window of 350 and 650 keV. Samples were
corrected for background and decay, and the percentage of the
injected dose per gram (%ID/g) was calculated.
Metabolite Analysis
C57BL/6 mice were injected with [18F]VM4-037 (21.27
±0.42 MBq). At 15 min (n=3) and 45 min (n=3), animals were
sacrificed and blood was collected via a heart puncture, centrifuged
(4 min, 4000 rpm), and plasma was harvested and diluted with
acidified water. An activated (10 ml of ethanol followed by 10 ml
of water) Waters tC18 Sep-Pak solid phase extraction cartridge was
used to separate the polar and apolar fractions, which were further
analyzed with HPLC (Dionex UltiMate 3000), using a Phenomenex
Gemini 5 μ, 250×10 column as stationary phase. The mobile phase
consisted of acetonitrile (A) and a 90 to 15 % gradient of 10 mM
phosphoric acid (B) at a flow of 3 ml/min.
Western Blotting
Tumors were minced and protein was isolated using RIPA buffer
completed with a protease inhibitor cocktail (complete EDTA-free;
Roche, Indianapolis, USA). Protein concentrations were determined
by Bradford assay (BioRad, Veenendaal, Netherlands) and protein
was separated on a 10 % SDS-PAGE gel. After blotting onto a
nitrocellulose membrane (GE Healthcare, Amersham Corp, UK) by
electrotransfer, membranes were blocked in 5 % non-fat dry milk
and probed overnight with antibodies against CAIX (M75, kindly
provided by S. Pastorekova, Institute of Virology, Slovak Academy
of Science, Bratislava, Slovak Republic) and β-actin (Cell
Signaling). Secondary antibodies (α-mouse IgG, Cell Signaling)
were detected with Western blot detection reagents (Thermo
Scientific Pierce, Rockford, USA).
Delta pH Assay
HT29 cells were seeded and incubated for 24 h under hypoxic
conditions (0.2 % O2, 5 % CO2, residual N2; MACS VA500
microaerophilic workstation, Don Whitley Scientific, Shipley, UK)
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with the addition of either vehicle (1 % DMSO), VM4-037 (1 mM),
or 4-(2-aminoethyl)benzene sulfonamide (AEBS; 1 mM), a positive
control for CAIX inhibition (n=4) [4]. The pH of the culture
medium was immediately measured at the end of each experiment,
as described in a previous study [14]. The inhibitory constant (Ki)
were obtained with a stopped-flow assay method [15].
Results
The inhibitory constant of VM4-037 was determined for
different carbonic anhydrases and showed a Ki of 124 nM for
CAIX while for CAI this was 168 nM, CAII 13.4 nM, and for
CAXII 61.3 nM (Fig. 1a). A delta pH assay was performed to
verify the CAIX-inhibiting potential of VM4-037. Upon
hypoxic conditions, the extracellular environment acidifies,
and this acidification is reduced upon incubation with either
VM4-037 or the positive control AEBS (Fig. 1b). To assess
CAIX expression in the in vivo tumors, protein levels were
evaluated by Western blot. Although there was variation, all
tumors expressed a certain level of CAIX (Fig. 1c).
PET acquisition was performed to investigate the distri-
bution of [18F]VM4-037 throughout the animal’s body and
to detect specific uptake in the tumor (Fig. 1d). At the first
time point, the shape of the mouse is clearly visible, and
high uptake is seen in the abdominal region. Over time, the
overall signal intensity decreased except for the abdominal
region. No signal was detected from the tumor region in any
of the scans. In the HT29 model, the shape of the animal was
also clearly visible, and high signals were detected in the
abdominal region. However, no accumulation was observed
in the tumor (Fig. 1d).
A biodistribution study performed on the U373 tumor-
bearing animals at 4 h p.i. showed that the organs with
more than 1 % ID/g [18F]VM4-037 uptake were the
colon, kidney, and liver, followed by the ileum, bladder,
and stomach (Fig. 1e). Disintegrations detected from the
tumor were not higher compared to background tissues
like the muscle, blood, and skin. Assessing the
biodistribution of [18F]VM4-037 at 2 h p.i. in the
HT29 tumor-bearing animals showed an uptake of above
30 % ID/g in the kidneys, ileum, and tissues and over
1 % ID/g in the liver, bladder, and stomach (Fig. 1e).
The percent injected dose per gram of the tumor was in
the same range as in the low-uptake organs.
Metabolite analysis of [18F]VM4-037 revealed 87.8±1.5
and 43.1±3.0 % of the tracer to be un-metabolized at 15 and
45 min p.i, respectively. Polar metabolites accounted for
11.1±2.0 %. Two apolar metabolites were found in the 45-
min samples, accounting for 27.2±1.9 and 17.1±3.6 %.
Discussion
This study investigated the distribution of [18F]VM4-037 in
tumor-bearing animals with the aim to determine the specific
accumulation in CAIX-expressing tumors. We assessed the
uptake of this tracer in two different CAIX-expressing tumor
models using microPET and biodistribution.
Doss et al. assessed the distribution of [18F]VM4-037 in
healthy volunteers [12], demonstrating the safety of this
CAIX PET imaging tracer. Consistent with their results,
both our microPET imaging and biodistribution data show a
high uptake of the tracer in the kidneys and liver at both 2
and 4 h p.i. Doss et al. also found that radiation dosimetry
showed high activity in the bladder at 4.8 h p.i. based on
voiding models [12]. In mice, this high-uptake organ was
detected at 2 h p.i. together with the colon, ileum, and
stomach. The difference in the pharmacokinetics of the
tracer in humans compared to mice could be explained by a
more rapid metabolism and clearance in mice. This may
indicate that at later time points, [18F]VM4-037 might non-
specifically accumulate in other human organs of the
abdominal region besides the kidney and liver.
The main goal of our study was to assess the specific
uptake of [18F]VM4-037 in CAIX-expressing tumors.
Although the U373 tumors expressed CAIX, as validated
by Western blot, microPET imaging could not distinguish
tumor tissue from background tissue. The observed spread in
CAIX expression in Fig. 1b is part of the natural variation
between the different tumors. A second tumor model with an
even higher and more stable CAIX expression was used and
was located on the shoulder of the animal preventing the
abdominal scatter from interfering with the signal from the
tumor. Furthermore, imaging was acquired more frequently
in the first 2 h p.i. to ensure coverage of all relevant time
points. However, at none of the time points was the tumor
distinguishable from the background, suggesting that the
tracer does not specifically accumulate in the CAIX-
expressing tumors. Biodistribution results were used to
clearly distinguish the uptake per organ, especially in the
high-uptake regions and the tumor. This confirmed that the
uptake of [18F]VM4-037 in the tumor was comparable with
the non-specific, overall distribution throughout the body of
the animals.
Recently, the uptake of [18F]VM4-037 was evaluated in
kidney cancer patients. Modest uptake signal was detected in
the tumors, but no correlation was found with staining for
CAIX and CAXII. The authors suggest that larger studies
are needed, since in this study only 11 patients underwent
imaging with [18F]VM4-037 [16]. Although CAIX is a
potential marker for clear cell renal cell carcinoma [17], it is
remarkable that uptake from the kidney tumors could be
distinguished since the current study, as well as the study
conducted by Doss et al., showed high non-tumor-related
uptake of [18F]VM4-037 in this organ.
A new CAIX targeting tracer [18F]4d has recently shown
to be clearly visible in HT-29 tumors [18]. Furthermore,
another CAIX targeting tracer (HE)3-ZCAIX:1, based on
Affibody molecules, has recently been developed and tested
in CAIX-expressing SK-RC-52 renal carcinoma xenografts.
The advantage of this new class of molecules is their small
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size resulting in favorable characteristics regarding extrava-
sation, tissue penetration, and clearance of unbound tracer.
These studies indicate that there is a general interest in
finding a specific marker to detect CAIX non-invasively
[19].
The question remains why no specific tracer accumula-
tion is observed in the tumor. There could be multiple
reasons for the discrepancy between the promising in vitro
results of VM4-037 and the lack of a signal from the tumor
in vivo. The radiopharmaceutical was 999 % pure at the
moment of injection, which means the radiopharmaceutical
could not be a reason for the unexpected low tumor uptake.
In vitro, the CAIX-expressing cells are easy accessible;
in vivo, however, the bioavailability is influenced by the
whole organism. Metabolite analysis showed that 43 % of
the tracer was still available in the blood plasma 45 min p.i.,
which should be sufficient for distribution throughout the
body and detection of CAIX at least on the early time points
investigated in this study. This indicates that metabolic
degradation could not be the cause for the low CAIX
specific accumulation. However, characteristics of the tumor
microenvironment that are absent in vitro could influence the
uptake of the tracer in the in vivo situation.
Conclusion
Although [18F]VM4-037 demonstrates some activity against
CAIX in the in vitro delta pH assay and in vivo metabolite
analysis are favorable, both our in vivo microPET and
biodistribution results show that the tracer does not
specifically accumulate in CAIX-expressing tumors.
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Fig. 1. [18F]VM4-037 in CAIX expression tumors. a Structure
formula of VM4-037 with Ki values for CAI, CAII, CAIX, and
CAXII. bIn vitro delta pH assay on HT29 cells exposed for
24 h to 0.2 % hypoxia either with vehicle, VM4-037, or the
positive control AEBS (n=4). Bars indicate mean plus SEM. c
Western blot analysis of U373 (number 1–4) or HT29 (number
5–7) protein samples from tumors excised from mice. The
bands of CAIX and actin are indicated. d microPET images of
mice bearing U373 (upper, corresponding to Fig. 1b mouse
1) or HT29 (lower, corresponding to Fig. 1b mouse 7) tumors
at multiple time points. High uptake in yellow/white, low
uptake in blue as represented by the color scale bars,
expressed as Bq/cc. White circle indicates location of tumor.
e Biodistribution at 4 and 2 h p.i. from U373 (n=4) or HT29
(n=4 mice, three of which had a tumor) tumor-bearing mice,
respectively. Bars indicate mean plus SEM.
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